Contact Us
Drug Search Results
More Filters [+]

GW-273225

Alternative Names: gw-273225, gw273225, gw 273225
Latest Update: 2017-08-08
Latest Update Note: Clinical Trial Update

Product Description

GW273225 is in development for epilepsy and bipolar disorder and can affect women of child bearing potential.

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GW-273225

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Epilepsy

Phase 1: Bipolar Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NEC107055

P2

Withdrawn

Epilepsy

2008-03-01

NEC107110

P1

Terminated

Bipolar Disorder

2007-11-16

NAP109169

P1

Completed

Bipolar Disorder

2007-10-11

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions